Oral Wegovy Formulation Now Available for Weight Management Following FDA Approval
Novo Nordisk just released the first oral glucagon-like peptide-1 receptor agonist for managing weight. Early in January 2026, pharmacies countrywide started selling the daily tablet after receiving regulatory approval. This release addresses accessibility issues with injectable treatment. As a result, the mixture offers patients a new strategy for managing their weight.
The Food and Drug Administration approved this oral formulation on December 22, 2025. Regulators based their decision on data from the Phase III OASIS 4 trial. Participants receiving the 25-milligram dose saw a mean weight reduction of 16.6 percent. Interestingly, one-third of the study participants lost more than 20% of their initial weight.
An analysis of all participants showed a mean weight loss of 13.6% when compared to the placebo group. Furthermore, compared to 76.3% of the therapy group, only 31.3% of the placebo group lost at least 5% of their body weight. These results validate the efficacy levels of the established weekly injectable semaglutide formulation.
The medicine was simultaneously approved by the agency to reduce cardiovascular risk and control chronic weight. Doctors may prescribe the therapy to adults with obesity or overweight along with weight-related health conditions. Additionally, the indication includes lowering the risk of significant cardiovascular events, such as cardiovascular death, nonfatal heart attacks, and nonfatal strokes, in people with pre-existing cardiovascular disease.
Participants in clinical trials reported gastrointestinal side effects characteristic of the class of glucagon-like peptide-1 receptor agonists. The most frequent adverse effects were nausea, vomiting, and diarrhea. However, compared to the placebo group, the active treatment group experienced fewer major adverse events. In particular, 3.9 percent of patients receiving treatment experienced severe incidents, compared to 8.8 percent in the placebo group.
The treatment must be taken on an empty stomach with only water. Patients should wait 30 minutes before consuming food or other medications. Dosing starts at 1.5 milligrams daily and increases monthly to reach 9 milligrams. Finally, the maintenance dose of 25 milligrams begins on day 91 to help reduce gastrointestinal reactions.
The oral tablet’s cost is significantly different from that of the current injectable alternatives. The initial dose will cost $149 per month for self-paying patients, after which it would increase to $199. The weekly injectable formulation, on the other hand, costs $499 per month without insurance. Assistance that reduces out-of-pocket expenses to roughly $25 is frequently available to patients with commercial insurance.
The recently approved oral formulation is presently manufactured in production facilities. In the second half of 2025, the corporation submitted regulatory applications to foreign agencies. Alternative oral glucagon-like peptide-1 receptor agonists are being developed by rivals in the meantime. Later in 2026, regulatory bodies want to examine rival agents such as orforglipron.
The OASIS 4 trial enrolled 307 adults who met specific body mass index criteria. Researchers excluded individuals with type 2 diabetes from the study. The active treatment group had an 18 percent discontinuation rate during the trial. In contrast, the placebo group had a higher discontinuation rate of 26 percent.
Beyond weight loss, post hoc analysis revealed improvements in glycemic management. In particular, more than 70% of individuals with prediabetes achieved normal blood glucose levels. Blood pressure readings also improved over the course of the research. These results provide evidence for metabolic advantages that go beyond weight loss.
